One prompt in. A fully sourced, verified research deliverable out, produced by a disciplined pipeline of AI agents, every figure traceable to a primary source.
The oncology kinase inhibitor market is estimated at USD 60.7B in 2025, with patent evidence anchored on patents.google.com.
Each stage hands its work to the next with its sources attached, so the finished deliverable carries an unbroken trail from prompt to primary source.
Write your brief in plain language and attach any internal models or files. Set breadth; depth is fixed at consulting-grade.
Eight specialized agents research, reason, graph, write and verify, with each step logged and every source retained and attributed.
An editorial report where every claim links to its evidence, reviewed, verification-badged, and export-ready as PDF.
Hover any figure in a deliverable and its evidence trail opens, revealing the exact excerpt, the primary URL, the agent that recorded it, and a confidence score. Provenance is not a feature here. It is the product.
Patent US-12606544-B2 links to patents.google.com in the live flagship run.
The oncology kinase inhibitor market is estimated at USD 60.7B in 20251, projected to reach USD 164.8B by 2035.
“...the oncology kinase inhibitor category is forecast to surpass USD 60B in worldwide sales by 2035, driven by second-generation entrants...”
evaluate.com/reports/oncology-kinase-2025
Second-generation kinase programs are reshaping a market estimated at USD 60.7B in 2025. This deliverable maps the patent estate, models share-shift under three scenarios, and anchors each conclusion to a primary filing or analyst source. Patent US-12606544-B2 is the IP anchor on patents.google.com.
Access is granted by our team after review. No self-serve checkout at MVP.
One seat, ten runs a month. For independent analysts.
Five seats, forty runs, shared workspace and review flow.
Unlimited seats, SSO, audit log, dedicated verification SLAs.